X

CONTACT  

Please email us with any questions or if you would
like a representative to contact you. contact@myoscience.com
For Media Inquiries, please contact mediarelations@myoscience.com
X

Website Terms of Use

Welcome to the myoscience, Inc. ("myoscience") web site. Myoscience maintains this Web Site to provide information to and communicate better with physicians, patients, investors, and others who may be interested in learning more about myoscience and the products and services it offers. You may use this Web Site, provided you comply with these terms and conditions.

Your Acceptance of These Terms and Conditions

Please take a few minutes to carefully review these terms and conditions. By accessing and using this Web Site you agree to follow and be bound by these terms and conditions. If you do not agree to follow and be bound by these terms and conditions, you may not access, use or download materials from this Web Site.

These Terms and Conditions May Change

Myoscience reserves the right to update or modify these terms and conditions at any time without prior notice. Your use of this Web Site following any such change constitutes your agreement to follow and be bound by the terms and conditions as changed. For this reason, we encourage you to review these terms and conditions every time you use this Web Site. These terms and conditions were last revised on August 25, 2011.

Copyright Notice and Limited License

Everything you see and hear on this Web Site (the "Content"), including, for example, all of the text, directories, photographs, illustrations, graphics, audio clips, video clips, and audio-video clips, is copyrighted under United States law and applicable international copyright laws and treaty provisions. The copyrights in the Content are owned by myoscience or by one of its affiliates, or by third parties who have licensed their materials to myoscience. The entire Content of this Web Site is copyrighted as a collective work under United States law and applicable international copyright laws and treaties. Myoscience owns the copyright in the selection, coordination, arrangement and enhancement of the Content. You may download, store, print, and copy selected portions of the Content of this Web Site, provided you:
Only use the Content you download for your personal, noncommercial use or to further your business dealings with myoscience.
Do not publish or post any part of the Content on any other Internet site without obtaining the prior written consent of myoscience.
Do not publish or broadcast any part of the Content in or on any other media without obtaining the prior written consent of myoscience.
Do not modify or alter the Content in any way or delete or modify any copyright or trademark notices or notices of confidentiality. No right, title or interest in the downloaded Content is transferred to you when you download Content from this Web Site. Myoscience reserves all intellectual property rights in any Content you download from this Web Site. Except as expressly stated above, you may not copy, download, print, publish, display, perform, distribute, transmit, transfer, translate, modify, add to, update, compile, abridge or in any other way transform or adapt all or any part of the Content without first obtaining written permission from myoscience.

Trademark Notice

All of the trademarks, service marks and logos displayed on this Web Site (the "Trademark(s)") are registered and unregistered trademarks of myoscience, one of its affiliates, or third parties who have licensed their Trademarks to myoscience or one of its affiliates. Except as expressly stated in these terms and conditions, you may not reproduce, display or otherwise use any Trademark without first obtaining myoscience's written permission.

Unsolicited Ideas

Myoscience welcomes your comments and feedback regarding this Web Site. All information and materials, including comments, ideas, questions, designs, and the like, submitted to myoscience through this Web Site will be considered NON-CONFIDENTIAL and NON-PROPRIETARY. For this reason, we ask that you not send us any information or materials that you do not wish to assign to us, including any confidential information or any original creative materials such as product ideas, computer code, or original artwork. By submitting information or materials to myoscience through this Web Site, you assign to myoscience, free of charge, all worldwide rights, title and interest in all copyrights and other intellectual property rights in the information or materials you submit. Myoscience will be entitled to use any information or materials you submit through this Web Site for any purpose whatsoever subject to our Privacy Policy, without restriction and without compensating you in any way.

Website Privacy Policy

Click here to view the myoscience Web Site Privacy Policy pertaining to the use of personal data collected through this Web Site, which is incorporated by reference as part of these Terms and Conditions.

Links to Other Web Sites

This site may contain hyperlinks to web sites that are not operated by myoscience. These hyperlinks are provided for your reference and convenience only, and do not imply any endorsement of the material or services provided on these third-party web sites or any association with their operators. Myoscience does not review or control these web sites and is not responsible for their content. Myoscience expressly disclaims any responsibility for the content of any third party web sites linked to our Web Site or the products or services of such third party. These third-party web sites (and the web sites to which they link) may contain information that is inaccurate, incomplete, or outdated. Myoscience does not make any representations regarding the content or accuracy of materials on such non-myoscience web sites or the products or services of any third party operating such web sites. You access and use these web sites (and the web sites to which they link) solely at your own risk.

Global Availability

Because different countries around the world have different laws and regulatory requirements, some medical devices and treatments are available in some countries and not in others. This Web Site contains references or cross references to myoscience products, programs and services that may not available or announced in your country. These references do not imply that myoscience intends to announce such products, programs or services in your country. Consult your local myoscience sales representative or contact myoscience if you have questions about which products, programs and services may be available to you.

Not a Substitute for Medical Advice

The information provided on this Web Site is not intended nor recommended as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider regarding any medical condition or treatment. Nothing contained on this site is intended to be for medical diagnosis or treatment.

DISCLAIMER OF WARRANTIES

THIS WEB SITE IS PROVIDED ON AN "AS IS," "AS AVAILABLE" BASIS, WITHOUT WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT POSSIBLE PURSUANT TO APPLICABLE LAW, MYOSCIENCE AND ITS AFFILIATES DISCLAIM ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF THIRD-PARTY RIGHTS. WITHOUT LIMITING THE FOREGOING, MYOSCIENCE DOES NOT REPRESENT OR WARRANT THAT THIS WEB SITE WILL BE AVAILABLE AT ANY PARTICULAR TIME OR LOCATION OR THAT ITS OPERATION WILL BE UNINTERRUPTED OR ERROR FREE. MYOSCIENCE DOES NOT REPRESENT OR WARRANT THAT THE CONTENT OF THIS SITE IS FREE OF VIRUSES, WORMS OR OTHER CODE THAT MAY MANIFEST CONTAMINATING OR DESTRUCTIVE PROPERTIES. IF YOUR USE OF THE WEB SITE OR THE MATERIALS RESULTS IN THE NEED FOR SERVICING OR REPLACING EQUIPMENT OR DATA, MYOSCIENCE IS NOT RESPONSIBLE FOR THOSE COSTS. USERS ARE RESPONSIBLE FOR PROTECTING THEMSELVES BY INSTALLING, UPDATING AND RUNNING ANTI-VIRUS PROGRAMS. INFORMATION PUBLISHED ON THIS WEB SITE MAY BE INCOMPLETE OR OUTDATED AND MAY CONTAIN INACCURACIES OR TYPOGRAPHICAL ERRORS. MYOSCIENCE DOES NOT WARRANT OR MAKE ANY REPRESENTATIONS REGARDING THE USE, VALIDITY, ACCURACY, CURRENCY, RELIABILITY OR COMPLETENESS OF, OR THE RESULTS OF THE USE OF, OR OTHERWISE RESPECTING THIS WEB SITE OR ANY INFORMATION, MATERIALS, SERVICES, SOFTWARE, TEXT, GRAPHICS AND LINKS CONTAINED ON OR ACCESSED THROUGH THIS WEB SITE. BECAUSE SOME JURISDICTIONS DO NOT PERMIT THE EXCLUSION OF CERTAIN WARRANTIES, THESE EXCLUSIONS MAY NOT APPLY TO YOU. MYOSCIENCE MAKES NO CLAIMS THAT THE MATERIALS ARE APPROPRIATE OR MAY BE DOWNLOADED OUTSIDE OF THE UNITED STATES. ACCESS TO THE MATERIALS MAY NOT BE LEGAL BY CERTAIN PERSONS OR IN CERTAIN COUNTRIES. IF YOU ACCESS THE WEB SITE FROM OUTSIDE OF THE UNITED STATES, YOU DO SO AT YOUR OWN RISK AND ARE RESPONSIBLE FOR COMPLIANCE WITH THE LAWS OF YOUR JURISDICTION.

LIMITATION OF LIABILITY

YOUR USE OF THIS WEB SITE IS AT YOUR SOLE RISK. UNDER NO CIRCUMSTANCES, SHALL MYOSCIENCE, ITS AFFILIATES OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS, BE LIABLE FOR ANY DIRECT OR INDIRECT LOSSES OR DAMAGES ARISING OUT OF OR IN CONNECTION WITH YOUR USE OF OR INABILITY TO USE THIS WEB SITE OR YOUR RELIANCE ON ANY INFORMATION PROVIDED ON THIS WEB SITE. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSSES AND DAMAGES OF ANY KIND WHATSOEVER, WHETHER DIRECT OR INDIRECT, GENERAL, SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR OTHERWISE, INCLUDING WITHOUT LIMITATION, LOSS OF DATA, REVENUE OR PROFITS. THIS LIMITATION OF LIABILITY APPLIES WHETHER THE ALLEGED LIABILITY IS BASED ON CONTRACT, NEGLIGENCE, TORT, STRICT LIABILITY OR ANY OTHER BASIS AND EVEN IF AN AUTHORIZED REPRESENTATIVE OF MYOSCIENCE OR ITS AFFILIATES HAS BEEN ADVISED OF OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.IF ANY PART OF THIS LIMITATION OF LIABILITY IS FOUND TO BE INVALID OR UNEN FORCEABLE FOR ANY REASON, THEN THE AGGREGATE LIABILITY OF MYOSCIENCE AND/OR ITS AFFILIATES UNDER SUCH CIRCUMSTANCES FOR LIABILITIES THAT OTHERWISE WOULD HAVE BEEN LIMITED SHALL NOT EXCEED ONE HUNDRED ($100.00) DOLLARS.

Indemnification

YOU AGREE TO DEFEND, INDEMNIFY, AND HOLD HARMLESS MYOSCIENCE, ITS OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS, FROM AND AGAINST ANY CLAIMS, ACTIONS OR DEMANDS, INCLUDING WITHOUT LIMITATION REASONABLE LEGAL AND ACCOUNTING FEES, RESULTING FROM YOUR USE OF THE MATERIALS (INCLUDING SOFTWARE) OR YOUR BREACH OF THE TERMS OF THIS AGREEMENT. MYOSCIENCE SHALL PROVIDE NOTICE TO YOU PROMPTLY OF ANY SUCH CLAIM, SUIT OR PROCEEDING OF WHICH IT RECEIVES NOTICE AND SHALL ASSIST YOU, AT YOUR EXPENSE, IN DEFENDING ANY SUCH CLAIM, SUIT OR PROCEEDING.

Governing Law and Jurisdiction

This Web Site is controlled and operated by myoscience from its offices within the State of California in the United States. Any claim relating to these Terms and Conditions and/or the use of this Web Site shall be governed by the laws of California. By using this Web Site, you consent to personal jurisdiction in the federal and state courts of California for any action arising out of or relating to this Web Site, these Terms and Conditions or your use of this Web Site. The federal and state courts of California shall have exclusive jurisdiction over all such actions.

Severability and No Waiver

If any provision of these Terms and Conditions is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of these Terms and Conditions shall remain in full force and effect. Any provision of these Terms and Conditions held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. No waiver of any term of this Agreement shall be deemed a further or continuing waiver of such term or any other term.

Entire Agreement

This Agreement constitutes the entire agreement between you and myoscience with respect to your access to and/or use of this Web Site and shall not be modified except by myoscience as provided herein or through a written document signed by both parties.

X

Our Privacy Policy

myoscience, Inc. ("myoscience") is committed to protecting your privacy. This Privacy Policy describes myoscience's current policies and practices with regard to personal data collected by myoscience through the myoscience.com web site (this "Web Site"). The term "personal data" refers to personally identifiable information about you, such as your name, birth date, e-mail address or mailing address, and any other information that is identified with you personally. By using our Web Site, you consent to the collection and use of this information as described herein.

Notification of Changes to this Policy

Myoscience is continually improving and adding new functionality and features to this Web Site and improving and adding to our existing products, services and programs. Because of these ongoing changes, changes in the law and the changing nature of technology, myoscience's data practices will change from time to time. If and when our data practices change, myoscience will post the changes on this page of our Web Site to notify you of the changes. We encourage you to check this page frequently by clicking on the Privacy Policy link on any page of our Web Site. This policy was last updated on August 25, 2011.

Personal Data Collected through myoscience.com

The only personal data myoscience currently collects through this Web Site is the information you send to us when you contact myoscience with your questions and comments through the Contact Us page on this Web Site. When you send us an e-mail through that page, we ask you for your name and other contact information, including, for example, your company's name, your e-mail address, and your mailing address or the mailing address of your company.

Use of Personal Data Collected through myoscience.com.

Myoscience does not sell, trade or rent your personal information to others. Myoscience uses the information you provide to respond to your e-mail, answer your question or resolve your problem. Myoscience and our affiliates also use this information to help us improve the content and functionality of our web sites, to better understand our customers and markets, and to improve our products and services. Myoscience and our affiliates may use this information to contact you in the future to tell you about products or services we believe will be of interest to you. If we do so, each communication we send you will contain instructions permitting you to "opt-out" of receiving future communications.

Anonymous Data Collected through myoscience.com

In addition to the information you provide when you use our Web Site, myoscience uses technology to collect anonymous information about the use of our Web Site. For example, we use technology to track how many visitors access our Web Site, the date and time of their visit, the length of their stay, and which pages they view. We also use technology to determine which Web browsers our visitors use and the address from which they accessed our site (for example, if they connected to myoscience.com by clicking on one of our banner ads). This technology does not identify you personally. It simply enables us to compile statistics about our visitors and their use of our Web Site. Myoscience and our affiliates use this anonymous data and share it with third parties to improve the content and functionality of our web sites, to better understand our customers and markets, and to improve our products and services.

Cookies

In order to collect the anonymous data described in the preceding paragraph, myoscience may use temporary "cookies" that collect the first level domain name of the user (for example, if your e-mail address is "bob@xyz.com," the cookie collects the "xyz.com" portion of your e-mail address) and the date and time you accessed this Web Site. Cookies by themselves cannot be used to discover the identity of the user. A cookie is a small piece of information which is sent to your browser and stored on your computer's hard drive. Cookies keep track of non-personal information such as the URL that you came from and go to next, your navigation through the website (for example, the advertisements that you click on), the browser and operating system that you use, and your IP address. Cookies do not damage your computer. You can set your browser to notify you when you receive a cookie. This enables you to decide if you want to accept it or not. At the present time, myoscience only uses temporary or "session" cookies. These cookies expire when your browser window is closed.

Disclosure of Your Personal Data

Myoscience may share some or all of the personal data collected through this Web site with our affiliates, who will only use this data in accordance with this Privacy Policy. Both Myoscience and our affiliates may share personal data collected through this Web Site with third-party vendors who act for or on behalf of myoscience or our affiliates, for example, companies that provide support services to us, including data processing services, or that help us market our products and services. These companies may need information about you in order to perform their functions. These companies are not authorized to use the information we share with them for any other purpose. In addition, there may be some other, limited circumstances in which myoscience or our affiliates may share or transfer the personal data in our databases, for example, to comply with a legal requirement to enforce the Terms and Conditions governing the use of this Web Site, to protect your interests, or in the event of a corporate sale, merger, reorganization, dissolution or similar event.

Children

Myoscience does not knowingly collect personal data from children under the age of thirteen. If you are under thirteen, please do not give us any personal data. If you have reason to believe that a child under the age of thirteen has provided personal data to myoscience, please contact us, and we will endeavor to delete that information from our databases.

Link to Other Sites

This Privacy Policy applies only to myoscience.com. Myoscience and our affiliates operate many different types of web sites for different purposes and in different countries where different laws may apply. If you visit another myoscience or one of our affiliates' web site, please take a moment to review the privacy policy posted on that site to learn what personal data may be collected through that site and how it is processed. Myoscience.com contains hyperlinks to web sites that are not operated by myoscience or one of our affiliates. These hyperlinks are provided for your reference and convenience only and do not imply any endorsement of the activities of these third-party web sites or any association with their operators. Myoscience does not control these web sites and is not responsible for their data practices. We urge you to review the privacy policy posted on any web site you visit before using the site or providing any personal data about yourself.

Governing Law

This Privacy Policy forms part of our Web Site Terms and Conditions and as such shall be governed by and construed in accordance with the laws of the California as further provided in the Terms and Conditions.

Questions About Our Privacy Policy

If you have any questions about this Privacy Policy or concerns about the way myoscience processes your personal data, please contact us.

X

TERMS & CONDITIONS

These terms & conditions are hereby incorporated into any transaction involving the sale, lease, rental, loan or licensing of Products, as defined below, by myoscience, Inc.

1.Definitions. "Authorized User" will mean a Licensed Physician or professional with substantial medical education and training who both: (a) possesses the training and qualifications required by applicable law to use the Products in accordance with this End User Agreement (the "Agreement") and (b) will use the device under company supervision until all training required by myoscience, Inc. ("Company") for the safe and proper use of the Products has been successfully completed within 90 days from Agreement execution and prior to reorder of Smart Tips. "Country of Use" will mean the country to which a Product was originally shipped by Company to the customer ("Customer"). "Licensed Physician" will mean a medical doctor in good standing that is licensed to practice medicine in the relevant jurisdiction at the time of the sale of the Products. "Products" will mean all products, supplies, documentation, training and other items purchased from Company by Customer and may be new or refurbished. Company is under no obligation to continue the manufacture of any Product.

2. Purchase of Products. Customer agrees to purchase and use Products in accordance with this Agreement. The purchase price for Products will be as communicated by Company from time to time and is subject to change at Company's sole discretion. Prices are exclusive of all taxes (including any excise, sales, use, value added, withholding and other taxes), import/export fees, customs duties and tariffs ("Taxes"), all of which will be Customer's responsibility. If Company is required to pay any Taxes, Customer will reimburse Company for all amounts paid. All payments will be made by means acceptable to Company in accordance with Company's then-current policies in.

3. Purchase Orders. This Agreement will exclusively govern all of Customer's orders for Products and will supersede any terms and conditions contained in Customer's purchase orders and other business forms, regardless of any failure of Company to object thereto. Customer will order all Products through a means acceptable to Company. No order will be binding on Company until accepted by Company in writing or Company ships the applicable Products.

4. Use of Products. (a) The Products will be used only by an Authorized User in the Country of Use. Any Authorized User who is not a Licensed Physician will use the Products only under the active supervision of a Licensed Physician. Allowing the use of any Products by any person other than an Authorized User who is, or is acting under the active supervision of a Licensed Physician may violate applicable law and may endanger patient safety. For purposes hereof, "active supervision" means having a Licensed Physician available during the performance of any procedure using the Products. (b) Customer will use, and will ensure that its employees and agents use, the Products only for their intended and approved uses and in accordance with this Agreement and all Company documentation and any updates thereto. (c) Customer will not sell, donate or otherwise transfer any Product to any third party, or export or re-export any Product or any Software contained therein, without Company's prior written consent and without all necessary United States and foreign government consents and licenses. (d) Customer will not tamper with, modify or assist any third party in modifying any Product. Company reserves the right not to sell any Products necessary for the continued use of any Products previously purchased if Company believes the Products are being used in violation of this Agreement.

5. Adverse Events. Customer will promptly (and in any event within two days) report to Company's Customer Service Department any malfunction of a Product or any injury arising out of use of a Product and provide all related information requested by Company.

6. Proprietary Rights. Company retains all proprietary rights, including all patents, copyrights and trade secrets, in and to all designs, engineering details and other technology and information pertaining to the Products. In furtherance of the foregoing, Company retains sole and exclusive ownership of all software included in or provided in connection with the Products (the "Software"), and Company hereby grants to Customer a non-exclusive, non-transferable license to use the Software as incorporated into, and solely for use in connection with, the Products in accordance with this Agreement. For clarity, the Software is licensed, and not sold, to Customer; any references to "sale" or "purchase" in this Agreement with respect to the Software mean the sale or purchase of such license. Customer will not (a) disassemble, decompile or otherwise reverse engineer the Software or any Product or (b) modify, copy, sell, rent, transfer, reproduce or distribute the Software. Upon at least 10 days notice, Customer will grant Company access to Products to install any new versions, updates or upgrades of the Software.

7. Trademarks and Advertising. Customer will comply with Company's trademark and advertising guidelines made available with Company's practice marketing kit and upon request. All goodwill derived from the use of Company trademarks will inure solely to the benefit of Company.

8. Delivery. Products will be shipped to Customer Ex Works (Incoterms 2010) Company's shipping point, at which time title and risk of loss will pass to Customer. Customer will be responsible for all shipping, clearance and forwarding costs. Company will not be liable for any delay in delivery.

9. Training. Customer will ensure that Customer and its employees and agents are fully trained with respect to the Products, and that Customer and its employees and agents comply with all applicable laws and regulations, including those of medical agencies and certification boards. Customer will ensure that its Authorized Users attend all training offered by or on behalf of Company that relates to safe use of the Products.

10. Warranty. Company warrants to Customer that the Products will be free from significant manufacturing defects in materials and workmanship during the Company's standard manufacturer's warranty period stated on the Sales/Lease Order Request. The sole and exclusive remedy of Customer for Company's breach of the foregoing warranty will be, at Company's option, the repair or replacement of a confirmed defective unit and such replacement may be with new or refurbished units. Except with respect to confirmed defective Products in breach of the foregoing warranty, Company conveys no right of return to Customer and no returns will be accepted. The foregoing warranty is contingent upon proper use of the Products by trained and authorized personnel in their intended and approved uses, and the foregoing warranty will not apply to items that were modified or otherwise altered or changed without Company's prior written approval, that were repaired by persons not authorized by Company, that were subjected to unusual physical, electrical or environmental stress or that were damaged during shipment to Customer. Except for the foregoing warranty, Company makes no warranty, express, implied or statutory, as to any matter whatsoever, including any warranty of merchantability, fitness for a particular purpose or non-infringement. The foregoing warranty applies only in favor of Customer who is the end user and original purchaser of the Products and is not transferable. Return of defective Products must be made according to Company's then-current return goods authorization procedures. Company will not accept any returns of sterile Products if the original packaging has been tampered with or opened, without Company's prior approval.

11. Limitation of Liability. Company's total aggregate liability arising out of this Agreement will be limited to the amount of the purchase price for the Product in question. Under no circumstances will Company be liable for any incidental, consequential, indirect, exemplary, punitive or special damages, including damages for lost revenue, profits or business opportunities, the cost of procurement of substitute goods or services or other financial losses. These limitations apply even if Company has been advised of the possibility of such damages, notwithstanding any failure of essential purpose of any limited remedy and regardless of the theory of liability.

12. Term and Termination. This Agreement will commence on the date of the last signature below and will continue in force until Company gives notice of termination. Sections 4–7, 11, and 13–15 will survive any termination, as well as all payment obligations incurred prior to termination.

13. Dispute Resolution. Any claim or dispute arising out of or relating to a Product or this Agreement will be resolved by binding arbitration conducted in the English language by a single arbitrator in San Francisco, California in accordance with the International Arbitration Rules of the American Arbitration Association. Judgment upon the arbitration award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Pending final determination of a claim through arbitration, a party may seek interim or provisional relief from a court of competent jurisdiction as necessary to protect the rights or property of such party.

14. Indemnity. Each party will indemnify the other party against all liabilities, claims and expenses (including reasonable attorneys' fees and other litigation expenses) incurred by that party against third parties arising from any breach or alleged breach of this Agreement by the respective party.

15. Miscellaneous. This Agreement sets forth the entire agreement of the parties regarding its subject matter, and supersedes all prior agreements and understandings relating to such subject matter. This Agreement will be governed by the laws of the State of California, U.S.A., without reference to principles of conflicts of law of any jurisdiction. This Agreement may not be assigned by Customer, by operation of law or otherwise, without Company's prior written consent. Company has the right to assign this Agreement without notice or consent. Any attempted assignment in violation of the foregoing will be null and void. No amendment of this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. If any provision of this Agreement is found to be invalid or unenforceable, the remainder of this Agreement will remain in full force and effect and be interpreted so as best to reasonably effect the intent of the parties.

Myoscience to Present New Data at the American Association of Hip and Knee Surgeons Annual Meeting

FREMONT, Calif. (GLOBE NEWSWIRE) – November 7, 2016 – Myoscience, Inc., a medical device company dedicated to its novel Focused Cold Therapy® technology for the treatment of pain, today announced that it will present data on the treatment of knee osteoarthritis at the upcoming American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting in Dallas, Texas, November 10-13, 2016.


Read More
X

PRESS RELEASES

MEDIA

 
2016

2016

Myoscience to Present New Data at the American Association of Hip and Knee Surgeons Annual Meeting

FREMONT, Calif. (GLOBE NEWSWIRE) – November 7, 2016 – Myoscience, Inc., a medical device company dedicated to its novel Focused Cold Therapy® technology for the treatment of pain, today announced that it will present data on the treatment of knee osteoarthritis at the upcoming American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting in Dallas, Texas, November 10-13, 2016.

Vinod Dasa, M.D., LSU, Department of Orthopaedics, will deliver the oral presentation, detailing data from a clinical study of the Company’s iovera° device used to freeze peripheral nerves in the knee associated with osteoarthritis pain. Details for the presentation are as follows:

Sunday, November 13, 7:34 a.m.

Session 7: Primary Total Knee

Paper #43: “Cryoneurolysis for Temporary Relief of Pain Associated with Knee Osteoarthritis: A Multi-center, Prospective, Double-Blind, Randomized, Controlled Trial”

The Company has also had a poster accepted for presentation at the meeting:

  • “Pre-operative Freezing of Sensory Nerves for Post-TKA Pain: Preliminary Results from a Prospective, Randomized, Double-Blind Controlled Trial”
    • Authors: Vinod Dasa, M.D. and Richard Berkowitz, M.D.
  • Attendees interested in more information can speak with Dr. Dasa at the iovera° booth (#402) on Saturday, November 12 from 3:30-4:30pm
 

ABOUT MYOSCIENCE

California-based Myoscience is a privately-held medical device company dedicated to improving patients’ lives by providing innovative, clinically proven, drug-free pain treatments. It’s iovera° system is powered by patented Focused Cold Therapy technology. The iovera° system is cleared in the US for the blocking of pain. For more information, please visit www.myoscience.com, or www.iovera.com.

 

 © 2016 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0424

###

Myoscience to Present New Data at the American Association of Hip and Knee Surgeons Annual Meeting
November 7, 2016 - Read Press Release

Myoscience to participate in Webcast on Pain targeting mechanism

FREMONT, CA (September 1, 2016) – Dr. Jessica Preciado, Director of Product Development and Principal Scientist of Myoscience, will participate in a BioPharma Dealmakers webcast, sponsored in part by Myoscience, featuring four companies innovating pain management therapies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am ET on October 6th.

> Webcast registration link

In this webcast, several companies that are working to target unmet needs in pain management will present their developments, which include analgesics with novel mechanisms of action, opioids with reduced potential for abuse and medical devices.

The webcast will also include a roundtable discussion and a Q&A section to allow you to hear direct expert opinions from the speakers and contribute your own thoughts.

Dr. Preciado earned her Ph.D. in Mechanical Engineering from UC Berkeley specializing in Biothermodynamics, specifically the use of cold applications in the body. She is the co-inventor of multiple patents and has authored several publications on topics such as cryobiology, cryoneurolysis and cryolipolysis. Other webcast participants include:

  • Dr. Jeffrey Herz, President and CEO of Algomedix, Inc
  • Dr. Derek Chalmers, CEO, President, and Director of Cara Therapeutics, Inc.
  • Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer of Nektar Therapeutics
  • Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.
 

ABOUT THE WEBCAST

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

ABOUT MYOSCIENCE

California-based Myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera° system. The iovera° system is cleared in the US for the blocking of pain. For more information, please visit www.myoscience.com, or www.iovera.com.

© 2016 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience.
###

Myoscience to participate in Webcast on Pain targeting mechanism
October 3, 2016 - Read Press Release

Breakthrough pain therapy device, iovera°, reaches max enrollment for two knee pain studies ahead of schedule; makes strong entry into orthopedic market

FREMONT, CA (March 1, 2016) – California-based Myoscience, Inc., announces the completion of patient enrollment in two prospective, randomized, placebo controlled studies focused on relieving knee pain.  Both studies measure the effect of using the proprietary, FDA cleared, iovera° treatment to freeze the peripheral nerves which transmit pain in the knee.  The iovera° treatment provides an immediate nerve block that is a non-systemic, non-narcotic solution to blocking pain for an extended period of time.  The iovera° treatment has been commercially available in the United States since March 2014.

The MYO-1070 study evaluates post-surgical pain management for patients treated prior to undergoing a total knee replacement; 150 patients were enrolled, the enrollment target was reached six weeks early.  The primary endpoint is cumulative opioid consumption at 6 weeks post-TKA surgery, comparing the iovera° treatment group and the control group. The MYO-0946 study evaluates iovera° as a temporary nerve block for patients with chronic knee pain due to osteoarthritis; 180 patients were enrolled.  The primary endpoint hypothesis of the study is that the change in score after 30 days under iovera° is superior to that of control.  Both studies will be critical at establishing the iovera° treatment as a non-systemic alternative for effective pain therapy.  Results of the studies will be available later this year.

Dr. Antonia Chen, orthopedic surgeon at the Rothman Institute in Philadelphia, Pennsylvania is an Investigator in MYO-1070. She sees the potential for therapies like the iovera° treatment - “Opioid abuse is becoming a larger problem in our society, and it may be beneficial to add non-narcotic pain therapies such as iovera° to reduce pain in our total knee replacement patients.”

Dr. Richard Berkowitz, orthopedic surgeon at the Phoenix Clinical Research Institute in Tamarac, Florida is also an Investigator in MYO-1070.  He feels it's a good fit for many orthopedic practices - “The duration of effect of the iovera° treatment will make it a useful adjunct for surgical applications especially knee replacement surgery.  Our staff have become experts on performing the treatment and it is a fast, safe and simple treatment to do in an office or hospital setting.”

The iovera° system is comprised of a handheld unit, charging dock and disposable Smart Tips, which deliver Myoscience’s patented Focused Cold Therapy® technology to treat peripheral nerves to block pain. Using the body's natural response to cold, the iovera° system can immediately relieve peripheral nerve pain – without the use of drugs or other systemic therapies.

Myoscience is expanding their commercial efforts by building an orthopedic distribution network in the United States and is exhibiting at the upcoming American Academy of Orthopaedic Surgeons annual conference in Orlando, Florida from March 2-4 (booth 3518).

Additional information on clinical studies for the iovera° treatment can be found on www.clinicaltrials.gov.

ABOUT MYOSCIENCE

California-based Myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera° system. The iovera° system is cleared in the US for the blocking of pain. For more information, please visit www.myoscience.com, or www.iovera.com.

© 2016 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience.  MKT-0398 REV A

Breakthrough pain therapy device, iovera°, reaches max enrollment for two knee pain studies ahead of schedule; makes strong entry into orthopedic market
March 1, 2016 - Read Press Release

2015

2015

Myoscience Expands Platform Technology for Pain Treatments to Reach Deep Peripheral Nerves

FREMONT, CA (Sep 9, 2015) – California based myoscience, inc., continues to revolutionize cryotherapy pain treatments with the release of the new 1x55mm Smart Tip for the iovera° device. The new Smart Tip consists of a single cannula that is 55mm in length, enabling physicians to reach peripheral nerves that are deeper in the body. This is the second Smart Tip released for the treatment of peripheral nerves to block pain with the iovera° device.

“With the launch of the 1x55mm Smart Tip, we have expanded the treatment possibilities,” says Jeff Gold, CEO of myoscience. “The current 3x6.9mm Smart Tip is excellent for superficial nerves and now, with the 1x55mm, we are able to reach a wide range of deep nerves, making the iovera° system a must-have treatment option for any physician specializing in pain.”

The iovera° treatment is powered by the Focused Cold TherapyTM delivery system, a patented miniaturization of traditional cryotherapy. Offering patients a non-systemic, minimally-invasive treatment for pain, physicians are excited about the possibilities with the 1x55mm Smart Tip.

David Smolins, MD, of Remedy Medical Group in Redwood City, CA says, "This is an exciting development for physicians and patients. The iovera° 1x55mm Smart Tip allows for cryoablative treatment of anatomy previously difficult to access. This greatly increases the conditions we can treat with this modality, benefitting the large population of patients seeking relief for their pain. iovera° is intuitive and easy to use, and its application in the treatment of lumbar conditions is very promising."

Over 2,000 commercial iovera° treatments have been performed to date in the U.S. Peripheral nerves treated with the iovera° system are temporarily stopped from signaling for a period of time, followed by a restoration of function. Results from the iovera° treatment can be felt immediately after treatment and last until the nerve has regenerated.

For physicians and patients who would like additional information, please visit www.iovera.com or email us directly at contact@myoscience.com.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by the Focused Cold Therapy delivery system, a patented miniaturization of traditional cryotherapy.  The ioveraº system is 510k cleared in the U.S. for the blocking of pain and general surgical use. For more information, please visit www.myoscience.com

© 2015 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

MKT-0384 REV A

Myoscience Expands Platform Technology for Pain Treatments to Reach Deep Peripheral Nerves
September 9, 2015 - Read Press Release

Myoscience Headquarters Moves to Fremont California - Primed for Growth

FREMONT, CA (Jul 23, 2015) – California-based myoscience, inc., announces the move of its headquarters office to Fremont, CA effective June 8th, 2015. As the second largest city in Silicon Valley, Fremont is home to dozens of innovative firms, such as Tesla, Thermo Fisher and Boston Scientific. A report by San Francisco-based SizeUp.com ranks Fremont as No. 1 in the U.S. for technology start-up businesses per capita, boasting 21 start-up companies for every 100,000 residents.

"This move to Fremont represents an important phase in the future of myoscience. The new office will give us greater flexibility and the space we need to accommodate our growth," says Jeff Gold, CEO of myoscience.

The new headquarters features a state of the art manufacturing facility that allows for expansion, achieving a sizable strategic directive. The iovera° system is comprised of a handheld unit, charging dock and disposable Smart Tips, which deliver myoscience’s patented Focused Cold TherapyTM technology to treat peripheral nerves to block pain. Using the body’s natural response to cold, the iovera° system can immediately relieve peripheral nerve pain – without the use of drugs or other systemic therapies.

Physicians nationwide have begun adopting the iovera° technology into their practices, seeing it as a leap forward in the treatment of pain. Many local physicians are already passionate believers in the results they have seen with their patients.

"The immediate and dramatic pain reduction that iovera° provides is a powerful motivator for behavioral change that I believe will transform the course of pain management from the passive use of medication to an active partnership between doctors and patients," says Barry Shibuya, MD, of Fremont Rheumatology and Fremont Holistic Center.

David Jupina, MD, of Tri-Valley Orthopedics in Pleasanton says, "I have seen positive early results with this exciting technology. This is another treatment option for patients that are dealing with musculoskeletal pain."

Those interested in the iovera° treatment for themselves or a loved one can find a physician on the iovera° health website at www.ioverahealth.com/doctors.php. Physicians providing the iovera° treatment in the San Francisco Bay Area include:

  • Dr. Craig Klooster, DPM/Podiatrist, Pleasanton and Stockton
  • Dr. Mannie Joel, Anesthesiologist/Pain Management, San Leandro
  • Dr. Michael Krinsky, Orthopedic Surgeon, Castro Valley
  • Dr. Santi Rao, Orthopedic Spine Surgeon, Concord and San Francisco
  • Dr. David Smolins, Anesthesiologist/Pain Management, Redwood City and San Francisco
 

Myoscience is located at 46400 Fremont Boulevard.

 

ABOUT MYOSCIENCE

California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is 510k cleared in the US for the blocking of pain. For more information, please visit www.myoscience.com

© 2015 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

Myoscience Headquarters Moves to Fremont California - Primed for Growth
July 24, 2015 - Read Press Release

New York City Pain Specialists Introduce New Treatment for Knee Pain First Physicians in Northeast to offer iovera° treatment

Redwood City, CA – February 23, 2015   Myoscience announced today that Dr. Halland Medical, and Manhattan Spine and Pain have joined a growing number of cutting-edge medical facilities in the nation, and become the first in the Northeast, to offer the iovera° system for the treatment of anterior and interior knee pain. The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold Therapy™ delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise, predictable, drug-free pain relief.

“The iovera° treatment provides my knee pain patients with a very effective, natural option that provides relief precisely at their point of pain allowing them, in many cases, to avoid or reduce their need for systemic painkillers,” said Sudhir Diwan, M.D., Manhattan Spine and Pain. “My patients are excited to have a minimally-invasive, drug-free treatment that enables them to walk out of my office pain-free and stay that way for up to 3 months.”

“Patients are relieved when they realize that there is a minimally-invasive, non-systemic option that can give them instant knee pain relief,” said Halland Chen, M.D., of Dr. Halland Medical. “There’s something familiar and comforting to patients about using the simple power of cold to eliminate pain, and with iovera° we can now use cold in a very high-tech, precise way to block specific nerve signals temporarily.”

Frequent knee pain limits function and mobility, and impairs quality of life for approximately 25% of adults.1 Peripheral nerves treated with the iovera° system are temporarily stopped from signalling for a period of time, followed by a restoration of function - results may vary per patient*. Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary.

“We are so pleased that these pain specialists have seen the unique value of the Focused Cold Therapy delivery system for patients with knee pain,” said Jeff Gold, myoscience CEO. “The iovera° treatment allows physicians to target a patient’s pain directly at the source by treating the specific peripheral nerves involved with a natural, safe dose of cold that temporarily stops the nerves from signalling and delivers immediate pain relief.”

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the handpiece to the Smart Tip, it undergoes a phase change becoming very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the handpiece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. The nerve re-innervates 1-2 mm per day, which gives a predictable restoration of nerve function.

About iovera°

The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. iovera° is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue.

About the Manhattan Spine and Pain Medicine

Manhattan Spine and Pain Medicine physicians listen and treat pain without surgery. Their passion is improving patients’ quality of life. Pain management is the medical specialty focused solely on treating patients in acute and chronic pain. The practice’s goal is to restore function and improve the quality of life for those in pain. The board-certified physicians at Manhattan Spine and Pain listen diagnose and treat pain from head to toe using a range of non-surgical treatment options. For more information about the Manhattan Spine and Pain Medicine please visit: https://treatingpain.com/mspm. Patients interested in iovera° treatment at Manhattan Spine and Pain can call 877-463-7264.

 

About Dr. Halland Medical

Dr. Halland Chen specializes in pain management. His practice is focused on non-surgical knee and spine treatments, with a special emphasis on regenerative medicine and organic options through the use of PRP, Stem Cells and natural supplements. Dr. Halland Medical applies its unique techniques for patients to address sports injuries, pain management conditions, and cosmetic anti-aging. Dr. Halland specializes in injection therapy and minimally invasive techniques. For more information about Dr. Halland Medical please visit: http://drhalland.com. Patients interested in iovera° treatment at Dr. Halland Medical can call: 212-464-8772.

 

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

MKT-0338 REV A

* In a single arm, post-market study of knee pain, 70% of subjects reported an effect at ~2 months.  45% of subjects reported a continued effect at ~3 months.

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

New York City Pain Specialists Introduce New Treatment for Knee Pain First Physicians in Northeast to offer iovera° treatment
February 23, 2015 - Read Press Release

Los Angeles-area Orthopedic Groups Become First in the Region to offer the iovera° treatment for Patients with Knee Pain

Redwood City, CA – January 22, 2015   Myoscience announced today that Kerlan-Jobe Orthopaedic Clinic and Podesta Orthopedic and Sports Medicine Institute have joined a growing number of cutting-edge medical facilities in the nation, and are the first in the Los Angeles area, to offer the iovera° system for the treatment of anterior and interior knee pain. The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold Therapy™ delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise, predictable, drug-free pain relief.

"We are pleased these practices have seen, first hand, the value of the iovera° system for their knee pain sufferers," said Jeff Gold, myoscience CEO. "The iovera° system gives physicians and patients a unique option to address peripheral nerve pain in a very targeted, safe way harnessing the natural power of cold to temporarily stop nerves from signaling and to deliver immediate pain relief without systemic medication."

Frequent knee pain limits function and mobility, and impairs quality of life for approximately 25% of adults.1 Peripheral nerves treated with the iovera° system are temporarily stopped from signalling for a period of time, followed by a restoration of function - results may vary per patient*. Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary.

"In my practice I strive to offer my patients options that are the least invasive to their bodies and lives as possible," said Luga Podesta, M.D., of the Podesta Orthopedic and Sports Medicine Institute. "This procedure uses the simple power of cold in a very high-tech, precise way to essentially block specific nerve signals temporarily and deliver immediate pain relief."

"The iovera° treatment has been a great addition to my clinical armamentarium for patients with knee pain. I can offer them highly targeted pain relief, and in many cases, help them avoid or reduce their need for systemic painkillers," said Vernon Williams, M.D., of Kerlan Jobe Orthopaedic Clinic. "My patients are excited to have a natural, drug-free treatment that enables them to walk out of my office with reduced pain and stay that way for up to 3 months."

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the handpiece to the Smart Tip, it undergoes a phase change becoming very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the handpiece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. The nerve re-innervates 1-2 mm per day, which gives a predictable restoration of nerve function.

About iovera°

The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. The iovera° system is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue.

About the Kerlan-Jobe Orthopaedic Clinic

The Kerlan-Jobe Orthopaedic Clinic is a world leader in the diagnosis and treatment of orthopaedic and sports medicine injuries and illnesses. In addition to sports medicine, the clinic specializes in all aspects of orthopaedic care, including the diagnosis and treatment of the spine, shoulder, elbow, knee, hand and foot disorders, orthopaedic trauma, arthritis, congenital disorders, and work-related injuries. The clinic also conducts research in the areas of sports medicine and orthopaedic care. For more information about the Kerlan-Jobe Orthopaedic Clinic please visit: http://www.kerlanjobe.com. Patients interested in the iovera° treatment at Kerlan-Jobe can call: 310-665-7200.

About the Podesta Orthopedic and Sports Medicine Institute

Founded in 2008 by Dr. Luga Podesta in Thousand Oaks, CA, the staff of physicians, nurses, medical assistants, and radiological technicians is dedicated to delivering exemplary care to patients, while minimizing potential time lost from work or play. The Institute has expertise in the treatment of athletic and musculoskeletal injuries of the shoulder, elbow, knee and spine utilizing a sports medicine model to aggressively diagnose and treat all patients with orthopedic musculoskeletal injuries. When appropriate, the Podesta team strives to take a conservative, non-surgical approach to treatment. For more information about the Podesta Orthopedic and Sports Medicine Institute please visit: http://podestasportsmedicine.com. Patients interested in iovera° treatment at the Podesta Orthopedic and Sports Medicine Institute can call: 805-267-2902.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0337 REV A

* In a single arm, post-market study of knee pain, 70% of subjects reported an effect at ~2 months.  45% of subjects reported a continued effect at ~3 months.

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

Los Angeles-area Orthopedic Groups Become First in the Region to offer the iovera° treatment for Patients with Knee Pain
January 22, 2015 - Read Press Release

2014

2014

Jeffrey Gold appointed Chief Executive Officer of myoscience

REDWOOD CITY, CA (October 31, 2014)  – myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer (CEO) effective immediately.  Mr. Gold, who previously held the position of President & COO, is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems.

“I am very pleased to handover the role of Chief Executive Officer to Jeff Gold.  Jeff is a seasoned executive with a solid record of success.  The myoscience Board of Directors fully supports the appointment and we are excited to have Jeff accept the leadership role as CEO,” said Rich Ferrari, myoscience Executive Chairman.

Prior to joining myoscience, Mr. Gold was the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest.  Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices.

“I am very excited to assume the responsibility of guiding myoscience through its next development stage,” said Gold.  “The myoscience team has built an extremely strong platform technology that targets two distinct markets, aesthetics (for facial wrinkles) and peripheral nerve pain, both with tremendous potential.  The patented iovera° product platform has demonstrated the ability to improve patients' lives in the aesthetics and pain management applications that is unmatched in those fields.  We have a strong team of dedicated professionals that will drive myoscience to greater success in the future.”

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.           MKT-0327 REV A

Jeffrey Gold appointed Chief Executive Officer of myoscience
November 3, 2014 - Read Press Release

Next advancement for the iovera° beauty treatment

REDWOOD CITY, CA (October 1, 2014)  – California based myoscience, inc. announced today the newest advancement in the iovera° beauty treatment for dynamic forehead wrinkles – the 1x55mm Round Smart Tip (155 Smart Tip).  The iovera° treatment is an exciting solution for those who want a quick toxin-free treatment for their dynamic forehead wrinkles. This next generation treatment utilizes a cannula like approach to provide a comfortable patient experience with immediate results that a physician can deliver in fewer than 20 minutes in their office. The treatment is currently available in Canada and the European Union.

An early partner and physician using iovera° in her clinic in Lebanon and Qatar, Dr. Nada Soueidan commented “I have been using iovera° since it was launched. The new treatment is quick and easy and patients are very pleased with the immediate and natural looking results – they can go directly from my office to their social engagements looking refreshed. This is a truly a revolutionary step in the advancement of natural aesthetic treatment options that was met with a great enthusiasm from patients, especially in the younger population and with men.”

Dr. Shirin Samimi-Fard shares the excitement of the new treatment and has seen the impact of offering a non-toxin treatment in her DermaLoft clinic in Gladbeck, Germany. “Over 80% of the patients I have treated with the new iovera° Smart Tip have been new patients to my clinic that were looking online for alternative treatment options.  The patients have been pleased with the results and that nothing was injected into their bodies.  I feel that I have a more complete offering for patients with the addition of iovera°.”

Jeff Gold, President and COO of myoscience notes the results with the new treatment. “We are very pleased with the speed and consistency of results with the newest iovera° beauty treatment.  Physicians are able to see the results during the treatment and deliver a customized effect for each patient before they leave the office.” Additionally he notes, “The overall trend towards natural treatment options is steadily increasing.  Statistics have shown that over 70% of consumers asked would consider a natural wrinkle treatment option1.  The iovera° treatment offers a simple, effective, non-toxin option for patients – the demand will continue to grow.”

For more information about the iovera° beauty treatment, please visit www.ioverabeauty.com

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

1 1506 respondents from London, Dusseldorf, Vancouver aged 25-50. Gender split: 75% female and 25% male. Fieldwork conducted: 14th-25th February 2014.

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.   MKT-0316 REV A

Next advancement for the iovera° beauty treatment
October 1, 2014 - Read Press Release

Bay Area Pain Specialists Freeze Out Knee Pain Becoming Among the First Clinics Nationwide to Offer the iovera° treatment

iovera° harnesses cold to block nerve signals and reduce pain

 Redwood City, CA – September 24, 2014   myoscience announced today the launch of its iovera° system for the treatment of anterior and interior knee pain at three practices in the San Francisco Bay area:  Remedy Medical Group, Fremont Holistic Center and California Spine Care.  The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold Therapy™ delivery system to apply a controlled cold zone via a Smart Tip to specific nerves for precise and predictable pain relief.

“We are pleased that these Bay Area pain specialists are joining the growing ranks of leading facilities in the nation offering the iovera° system for knee pain sufferers,” said Jeff Gold, myoscience President and Chief Operating Officer.  “The iovera° treatment gives physicians the opportunity to safely address their patients’ peripheral nerve pain – the immediate result allows them to see the relief and the subsequent excitement first hand.”

Frequent knee pain affects approximately 25% of adults, limits function and mobility, and impairs quality of life.1 Peripheral nerves treated with the iovera° system stop signaling pain for a set period of time, usually up to 3 months, after which their function is restored.  Because peripheral nerve function is disrupted rather than destroyed, the treatment is safe, effective and temporary.

“iovera° is unique in that it offers safe, highly targeted pain relief right at the peripheral nerve involved in a patient’s pain,” said David Smolins, M.D., Remedy Medical Group.  “It’s exciting to see so many of my patients come in with debilitating knee pain and walk out of my office pain-free after their first iovera° treatment.”

“Our patients are delighted to have the option of a non-invasive, drug-free treatment that specifically targets the area of pain,” said Santi Rao, M.D., California Spine Care.  “We are finding that if patients can avoid or reduce their use of systemic medicines and their side effects, they prefer that option.”

“Our patients are achieving immediate and sustained pain relief which allows them to comfortably pursue and make progress in physical therapy, but also, and perhaps more importantly, get back to the activities that matter most to them,” said Barry Shibuya, M.D, Founder and Medical Director, Fremont Holistic Center.

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment.  While this highly pressurized liquid travels from the hand piece to the Smart Tip, it undergoes a phase change and becomes very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the hand piece, leaving nothing behind in the body.  This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system.  Pain relief can last up to 3 months, at which time predictable restoration of nerve function occurs.

About iovera°

The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013.  The iovera° system is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature.  It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue. www.ioverahealth.com

About Fremont Holistic Center

Fremont Holistic Center, located in Fremont, CA, integrates the best of Western and non-Western practices through a therapeutic relationship to care for the entire person (mind, body and spirit).  For more information about Fremont Holistic Center please visit: http://www.fremontholistic.com. Patients interested in iovera° treatment at the center can call: 510-585-3055.

About Remedy Medical Center

Remedy Medical Center, with offices in Redwood City and San Francisco, CA, understands that patient health and wellness begins today. The Center’s medical team has been selected and organized in order to effectively practice all aspects of Physical Medicine and Rehabilitation, and Pain Management.  Remedy provides diagnosis, medication management, interventional care, patient education, as well as alternative therapies. For more information about Remedy Medical Center please visit: http://www.remedydocs.com. Patients interested in iovera° treatment at the center can call: 415-819-6575.

About California Spine Care

California Spine Care, located in San Francisco, Concord and Sacramento, CA, is dedicated to the care and treatment of people with neck, back and joint pain.  The center provides a thorough evaluation, comprehensive diagnosis, and treatment plan for its patients.  They specialize in non-surgical techniques, injection treatments, as well as state of the art surgery options.  For more information about California Spine Care please visit: Patients interested in iovera° treatment at the center can call: 925-691-1700.

About myoscience 

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

© 2014 myoscience. All rights reserved.  iovera° and Focused Cold Therapy are trademarks of myoscience.

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

Bay Area Pain Specialists Freeze Out Knee Pain Becoming Among the First Clinics Nationwide to Offer the iovera° treatment
September 24, 2014 - Read Press Release

Louisiana State University Department of Orthopaedic Surgery Becomes One of the First Clinics Nationwide to Offer iovera° Focused Cold Therapy to Freeze Out Knee Pain

iovera° harnesses cold to block nerve signals and reduce pain

 

Redwood City, CA – July 16, 2014   myoscience announced today the launch of its iovera° system for the treatment of anterior and interior knee pain at the Louisiana State University (LSU) Department of Orthopaedic Surgery.  The iovera° system utilizes its patented Focused Cold Therapy™ delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise and predictable pain relief.

“We are excited that LSU is among the first cutting edge orthopaedic facilities in the nation to offer the iovera° system for knee pain sufferers,” said Clint Carnell, myoscience CEO and iovera° developer.  “iovera° gives physicians the opportunity to address their patients’ peripheral nerve pain in a very targeted way harnessing the natural power of cold to temporarily stop nerves from signalling and to deliver immediate toxin-free, drug-free pain relief.”

Frequent knee pain affects approximately 25% of adults, limits function and mobility, and impairs quality of life.1 Peripheral nerves treated with the iovera° system stop signalling pain for a set period of time, usually up to 3 months, after which their function is fully restored.  Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary.

“This technology has the potential to change the current paradigm of acute and chronic pain management.  The patients that I have treated are all grateful to have an option that is very safe and that has allowed them to get back to functionality quickly,” said Vinod Dasa, MD, Assistant Professor of Clinical Orthopaedics at the Louisiana State University Health Sciences Center (LSUHSC) School of Medicine in New Orleans, one of the first U.S. physicians to perform the procedure and to treat more than 60 patients.  “Focused cold therapy offers reliable pain relief in areas such as the knee which may allow for physical therapy to proceed, and even reduce the need for systemic pain relievers.”

The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment.  While this highly pressurized liquid travels from the hand piece to the Smart Tip, it undergoes a phase change

and becomes very cold drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the hand piece, leaving nothing behind in the body.  This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system.  Pain relief can last up to 3 months, at which time predictable restoration of nerve function occurs.

About iovera°

The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013.  The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature.  It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue.

About LSU Department of Orthopaedic Surgery

The Department of Orthopaedic Surgery at LSUHSC in New Orleans is dedicated to training excellent orthopaedic surgeons while providing exemplary patient care.  The department has many internationally recognized faculty members. The faculty is fellowship-trained in all specialties and is dedicated to continued scholarly activities. Many faculty members are involved in innovative research. A unique feature of the LSU orthopaedic department is the multi-disciplinary approach to treating orthopaedic conditions and the treatment of the ‘whole’ patient for maximum function.  For more information about The Department of Orthopaedic Surgery at LSUHSC, a member of the LSU Healthcare Network, please visit: http://www.lsuhn.com/.  Patients interested in iovera° treatment at LSUHSC can call: 504.412.1700.

 

About myoscience  

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved.  iovera° and Focused Cold Therapy are trademarks of myoscience.

                                            

1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.

Louisiana State University Department of Orthopaedic Surgery Becomes One of the First Clinics Nationwide to Offer iovera° Focused Cold Therapy to Freeze Out Knee Pain
July 16, 2014 - Read Press Release

myoscience Named Winner of the 2014 Red Herring Top 100 North America Award

REDWOOD CITY, CA (May 21, 2014) – California based myoscience, inc., makers of the revolutionary iovera° system for treatment of peripheral nerves, has been named a winner of the prestigious Red Herring 2014 Top 100 North America Award. As a winner, myoscience joins a short list that honors the year’s most promising private companies. Starting from a field of over 3,000 candidates, myoscience was selected as a Top 100 winner by Red Herring.

Award winners were selected using a rigorous evaluation process that included both quantitative and qualitative criteria, such as financial performance, technological innovation and intellectual property, management quality, business model, customer footprint and market penetration.

Myoscience’s groundbreaking iovera° treatment utilizes the body’s natural response to cold to deliver immediate results for both therapeutic and aesthetic applications. The iovera° system is FDA cleared for the treatment of pain in the United States and is approved in the European Union and Canada for the treatment of wrinkles.

“In 2014, selecting the top 100 achievers was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring.“ In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early. But after much thought, rigorous contemplation and discussion, we narrowed our list down from all the candidates across North America to the top 100 winners. We believe myoscience embodies the vision, drive and innovation that define a successful entrepreneurial venture. Myoscience should be proud of its accomplishment, as the competition was very strong.”

“We are proud of our team, grateful to our investors, and very honored to have been selected for this highly coveted distinction,” said myoscience CEO Clint Carnell. “This selection further validates the hard-work and dedication of our team in bringing this remarkable platform technology to patients around the world.”

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

 

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.    MKT-0250 REV A

myoscience Named Winner of the 2014 Red Herring Top 100 North America Award
May 21, 2014 - Read Press Release

Forbes Living Features iovera° by myoscience, Inc.

May 20, 2014, St. Petersburg, FL – The producers of Forbes Living are excited to announce that the iovera°® health treatment, an innovative peripheral nerve pain treatment designed by myoscience, Inc., will be featured in an upcoming segment as part of their "Healthy Living" series.  The show is hosted by Forbes Riley, an award-winning TV host in the D2C industry, author, entrepreneur, mother and one of the nation’s leading health and wellness experts.

The primary function of a peripheral nerve is to transmit signals from the spinal cord to the rest of the body, and to return signals sensing things like pain from the rest of the body to the spinal cord. Damage to peripheral nerves can cause severe pain, affecting one's quality of life and emotional well-being.

The team at myoscience has harnessed the healing power of cold to treat peripheral nerves that signal pain.  The iovera° treatment utilizes myoscience’s platform technology, the Focused Cold Therapy™ delivery system, to precisely target peripheral nerves, temporarily interrupting pain signaling pathways. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration that is followed by a predictable restoration of nerve function.  The iovera° system offers patients a new non-habit forming treatment option, with no systemic side effects and nothing being injected into the body. Most patients experience instant pain relief after an iovera° treatment, with results that can last up to three months.

The iovera° treatment is minimally invasive and can be performed inside a physician's office. Patients benefit from an immediate reduction in pain. The average treatment time for one treatment site is approximately 20-30 minutes.

”The opportunity to work with Forbes to educate consumers about this breakthrough pain treatment will be a big step in spreading the word about how the power of cold can treat pain," said Clint Carnell, CEO of myoscience. "We are pleased to be partnering with such a respected program."

Forbes Living features the revolutionary iovera° treatment for peripheral nerve pain  developed by myoscience.  For more information about the iovera° treatment, please visit www.ioverahealth.com.

About Forbes Riley

Forbes Riley, recently named America's Most Loved Health & Fitness Innovator, is known for bringing affordable, high-quality fitness, health, and household products to consumers worldwide. Recognized for her marketing prowess, Riley is famous for launching products that solve tough challenges and make everyday life easier. This includes some of the most successful product promotions of all time, including the Jack LaLanne Juicer. As the co-creator, co-executive producer, and host of Forbes Living, Riley motivates others by informing, educating, branding, and creating consumer awareness on a variety of products. Riley boasts a huge following on her website and on social media. She also has a regular presence on networks including ESPN, TLC, Fit-TV, Animal Planet, ABC Family, and Home Shopping Network.

About Forbes Living

The groundbreaking talk show combines the most highly recognized product spokeswoman with new and innovative products designed to engage viewers in a fun, informative, and entertaining fashion. Watch out for upcoming broadcasts nationally on WE TV (Women’s Entertainment ©™), Discovery Channel Transponder®™, Lifetime Real Women™, Esquire Network™, and DIY Network Canada.  The talk show will also air regionally on ABC, FOX, and ION broadcast affiliates.  Join the interactive fun with Forbes Living on Facebook, Twitter and LinkedIn pages. The show's website provides a contact form that business owners can fill out to receive more information. Forbes Living is an FR Media production.

About FR Media

FR Media brings a superior track record of award-winning video and film background services including video and film, direct response television, commercial advertising, and media planning and buying. Staffed with Emmy, Telly and Moxie award-winning staff members from the disciplines of television, DRTV, film, print, advertising and online media, FR Media studios are located in St. Petersburg, Florida. If you have a product you would like considered for the show, go to www.forbeslivingtv.com and fill out our Product Inquiry form.

Forbes Living Features iovera° by myoscience, Inc.
May 20, 2014 - Read Press Release

myoscience, inc. is a Finalist for the 2014 Red Herring Top 100 North America Award

REDWOOD CITY, CA (May 07, 2014) – California based myoscience, inc., makers of the revolutionary iovera° system for treatment of peripheral nerves, announced today it has been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.

Red Herring has been selecting the most exciting and promising start-ups and "scale ups" since 1995. Finalists are still evaluated individually from a large pool of hundreds of candidates based across North America. Twenty major criteria underlie the scoring and process. The list of finalists often includes the best performing and prominent companies of that year.

“We are honored to be recognized as a finalist for this award,” said myoscience CEO Clint Carnell.  “I'm proud to see the efforts of our talented employees recognized. Their hard-work and dedication the past 9 years bringing this remarkable platform technology to the world will change the landscape of treating peripheral nerve conditions."

Myoscience’s groundbreaking iovera° treatment harnesses the power of cold with the Focused Cold TherapyTM delivery system and delivers immediate results for both therapeutic and aesthetic applications.  The iovera° treatment does not use toxins, chemicals, or pharmaceuticals to achieve results and leaves nothing behind in the body. The iovera° system is FDA cleared for the treatment of pain in the United States and is approved in the European Union and Canada for the treatment of wrinkles.

2014 will be remembered as a special vintage. "The finalists list confirms the excellent choices made by entrepreneurs and VCs and the start-ups' solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States’ entrepreneurial excellence," said Alex Vieux, publisher and CEO of Red Herring.

Finalists are asked to present their winning strategies at the Red Herring North America Forum in Monterey, Calif., May 14 to 16, 2014. The Top 100 winners will be announced at a special awards ceremony the evening of May 16 at the event.

Please follow the Red Herring conference at https://twitter.com/digitalherring hashtag #RedHerring100

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0234 REV A

 

myoscience, inc. is a Finalist for the 2014 Red Herring Top 100 North America Award
May 7, 2014 - Read Press Release

Novel pain treatment is now available: iovera° system harnesses the power of cold to block pain

REDWOOD CITY, CA (May 01, 2014) – California based myoscience, inc., is pleased to announce the launch of the revolutionary iovera° health treatment, a new option to immediately block pain using the body’s natural response to cold without the use of drugs or surgery.

Vinod Dasa, MD, Associate Professor of Orthopaedic Surgery in New Orleans, one of the first to perform the treatment has treated over 50 patients and is excited about the possibilities. “I think this technology has the potential to change the current paradigm of acute and chronic pain management.  The patients that I have treated are all grateful to have an option that is very safe and that has allowed them to get back to functionality quickly.”

Clint Carnell, CEO of myoscience, has witnessed the powerful patient outcomes “It’s rewarding to provide this revolutionary treatment to patients suffering from pain. We have developed a product that delivers a treatment that is safe, effective and most importantly free of the negative systemic side effects often common with today’s therapeutic options.”

The iovera° health treatment utilizes myoscience’s platform technology, the Focused Cold TherapyTM delivery system, to precisely target peripheral nerves, temporarily interrupting pain signaling pathways. This precise cold treatment causes a reversible nerve block based on a process called 2nd degree degeneration that is followed by a predictable restoration of nerve function.  The iovera° system offers patients a new treatment option, with no systemic side effects and nothing being injected into the body. Most patients experience instant pain relief after an iovera° treatment, with results that can last up to three months.

For physicians and patients who would like additional information, please visit www.ioverahealth.com or email us directly at contact@myoscience.com.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

MKT-0229 REV A

Novel pain treatment is now available: iovera° system harnesses the power of cold to block pain
May 1, 2014 - Read Press Release

Jeffrey Gold joins myoscience as President and Chief Operating Officer

REDWOOD CITY, CA (April 16, 2014)  – myoscience, inc. is pleased to announce the addition of Jeffrey Gold to the team as President and Chief Operating Officer (COO).  Mr. Gold is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems.

“Jeff’s leadership and extensive experience driving operational excellence makes him an exceptional addition to myoscience as we expand our global commercial presence in both aesthetic and therapeutic channels,” said Clint Carnell, CEO of myoscience.

Mr. Gold was most recently the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest.  Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices.

“I am thrilled to be joining myoscience at such an exciting point in their growth,” said Gold. “My previous experience and the current needs of the company align perfectly and I look forward to guiding the business towards further success.”

 

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

MKT-0226 REV A

Jeffrey Gold joins myoscience as President and Chief Operating Officer
April 23, 2014 - Read Press Release

Vancouverites looking for natural beauty

 

  • New cosmetic treatment iovera° uses body’s natural response to cold to smooth forehead wrinkles
  • Survey reveals over half of Vancouverites would consider non-surgical cosmetic treatment
  • 30-35 age group most concerned with looking younger

Vancouver, April 2014 - A survey conducted by new cosmetic wrinkle treatment iovera°® has found that there is a growing desire among Vancouverites for more natural beauty products and treatments.  Two thirds of respondents (67%) said that they have become more aware of the ingredients in cosmetics and beauty products in the last two years.  While quality (58%) and price (51%) are important, natural ingredients (39%) ranked highly on factors influencing purchasing decisions.

The iovera° treatment provides a new option for people who want to treat their dynamic forehead wrinkles but who are uncomfortable or unsuitable for existing treatments which use a toxin.  The effects of the 20 minute procedure targets forehead lines precisely using the Focused Cold TherapyTM delivery system. The Focused Cold Therapy delivery system is an advanced technology that works immediately and relaxes facial muscles that cause wrinkles without leaving any toxins or chemicals behind in the body. The effects of the treatment last up to 3 months.

The survey of more than 500 Vancouverites found that appearance matters with the majority (80%) of those questioned admitting they put a great deal or quite a lot of effort into looking their best.  72% of women surveyed claimed they would be unlikely to go out and meet friends without doing their hair and makeup.  They are not alone, as 62% of men would not go out without doing their hair.

Living and looking healthy is also important to Vancouverites. Nine out of ten (90%) of those polled said they would like to lead a healthier lifestyle and many will check the label for artificial ingredients and preservatives in foods (73%) and beauty (60%) products.

Ultimately people would like to look younger (72%) and healthier (86%) and just over half (54%) said they would consider a non-surgical cosmetic treatment to smooth forehead lines and wrinkles.

Dr. Charles Cheng, MD at Skin Matters and iovera° trained doctor said, "The iovera° system provides instant gratification for those seeking a non-toxin option for wrinkle prevention and reduction.  This technology shows incredible promise and should prove to become one of the leading choices in wrinkle treatment for doctors and patients alike.”

76% of respondents who would consider a cosmetic wrinkle treatment find the idea of a treatment, which uses the body’s natural response to cold more appealing, compared to one in nine (11%) that find a treatment, which uses a toxin more appealing.  Fear of looking fake, plastic or unnatural is the biggest fear among those who would not consider such a treatment.

Clint Carnell, CEO of myoscience who developed the iovera° treatment in California, is positive about the growing interest being shown for the treatment in Canada: “The iovera° technology enables physicians to treat using only the power of cold which is an appealing option for many.”

“We developed iovera° in partnership with some of the world’s leading physicians. There is powerful consumer demand for the treatment because it offers an immediate wrinkle solution without the use of a toxin,” says Clint.

 

ENDS

 

Notes to editors:

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Vancouverites looking for natural beauty
April 10, 2014 - Read Press Release

Germans looking for natural beauty

  • New cosmetic treatment - iovera°® - uses body’s natural response to cold to smooth forehead wrinkles
  • Survey reveals nearly two thirds of people in Düsseldorf would consider non-surgical cosmetic treatment
  • 35-39 age group most concerned with looking younger

March 2014 - A survey conducted by new cosmetic wrinkle treatment iovera° has found that there is a growing desire among Düsseldorf citizens for more natural beauty products and treatments.  The majority of respondents (60%) said that they have become more aware of the ingredients in cosmetics and beauty products in the last two years.  While quality (72%) and price (50%) are important, natural ingredients (38%) ranked highly on factors influencing purchasing decisions.

The iovera° treatment provides a new option for people who want to treat their dynamic forehead wrinkles but who are uncomfortable or unsuitable for existing treatments which use a toxin. The 20 minute procedure targets forehead lines precisely by using the Focused Cold TherapyTM delivery system. The Focused Cold Therapy delivery system is an advanced technology that works immediately and relaxes facial muscles that cause wrinkles without using toxins and without leaving chemicals behind in the body. The effects of the treatment last up to 3 months.

The survey of more than 500 Düsseldorf citizens found that appearance matters with nearly half (45%) of those questioned admitting they put a great deal or quite a lot of effort into looking their best.  61% of women surveyed claimed they would be unlikely to go out and meet friends without doing their hair and makeup.  They are not alone as 46% of men would not go out without doing their hair.

Living and looking healthy is also important to people in Düsseldorf. Eight out of ten (83%) of those polled said they would like to lead a healthier lifestyle and many will check the label for artificial ingredients and preservatives in foods (70%) and beauty products. (67%)

Ultimately people would like to look younger (63%) and healthier (80%) and nearly two thirds (62%) said they would consider a non-surgical cosmetic treatment to smooth forehead lines and wrinkles.

Dr. med. Afschin Fatemi, Medical Director at S-thetic Clinic Düsseldorf and iovera° trained physician said, "Patients at my clinic seek treatments that will provide them a natural look, one that leaves them looking fresh and rejuvenated. The iovera° treatment allows me to offer this result with the added benefit that no toxins are actually injected into the body. I’ve been using this innovative treatment at my clinic since March 2013, and both my patients and I are very excited about the potential of iovera° and its immediate result.”

Of respondents who would consider a cosmetic wrinkle treatment, 70% find the idea of a treatment which uses the body’s natural response to cold more appealing, compared to one in six (17%) that find a treatment which uses a toxin more appealing.  Looking fake, plastic or unnatural is the biggest fear among those who would not consider a toxin treatment.

Clint Carnell, CEO of Myoscience, the company that developed the iovera° treatment in California, is positive about the growing interest being shown for the treatment in Germany: “The iovera° technology enables physicians to treat using only the power of cold which is an appealing option for many.”

“We developed iovera° in partnership with some of the world’s leading physicians. There is powerful consumer demand for the treatment because it offers an immediate wrinkle solution without the use of a toxin,” says Carnell.

 

ENDS

 

Notes to editors:

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, the Focused Cold TherapyTM delivery device, the standard of care for the treatment of peripheral nerve conditions. The Focused Cold Therapy delivery device is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Germans looking for natural beauty
April 8, 2014 - Read Press Release

Londoners looking for natural beauty

  • New cosmetic treatment iovera° uses body’s natural response to cold to smooth forehead wrinkles
  • Survey reveals over half of Londoners would consider non-surgical cosmetic treatment
  • 30-35 age group most concerned with looking younger
London, March 2014 - A survey conducted by new cosmetic wrinkle treatment iovera°® has found that there is a growing desire among Londoners for more natural beauty products and treatments.  Two thirds of respondents (65%) said that they have become more aware of the ingredients in cosmetics and beauty products in the last two years.  While quality (59%) and price (48%) are important, natural ingredients (32%) ranked highly on factors influencing purchasing decisions.

The iovera° treatment provides a new option for people who want to treat their dynamic forehead wrinkles but who are uncomfortable or unsuitable for existing treatments which use a toxin.  The effects of the 20 minute procedure targets forehead lines precisely using the Focused Cold TherapyTM delivery system. The Focused Cold Therapy delivery system is an advanced technology that works immediately and relaxes facial muscles that cause wrinkles without leaving any toxins or chemicals behind in the body. The effects of the treatment last up to 3 months.

The survey of more than 500 Londoners found that appearance matters with the majority (59%) of those questioned admitting they put a great deal or quite a lot of effort into looking their best.  54% of women surveyed claimed they would be unlikely to go out and meet friends without doing their hair and makeup.  They are not alone as 43% of men would not go out without doing their hair.

Living and looking healthy is also important to Londoners. Nine out of ten (90%) of those polled said they would like to lead a healthier lifestyle and many will check the label for artificial ingredients and preservatives in foods (76%) and beauty (62%) products.

Ultimately people would like to look younger (73%) and healthier (89%) and just over half (54%) said they would consider a non-surgical cosmetic treatment to smooth forehead lines and wrinkles.

Dr Yannis Alexandrides, MD at 111 Harley Street and iovera° trained doctor said, "Patients at my clinic seek treatments that will provide them a natural result, one that leaves them looking fresh and rejuvenated. iovera° allows me to offer this result with the added benefit that no toxins are actually injected into the body."

68% of respondents who would consider a cosmetic wrinkle treatment find the idea of a treatment which uses the body’s natural response to cold more appealing, compared to one in five (22%) that find a treatment which uses a toxin more appealing.  Fear of looking fake, plastic or unnatural is the biggest fear among those who would not consider such a treatment.

Clint Carnell, CEO of myoscience who developed the iovera° treatment in California, is positive about the growing interest being shown for the treatment in the UK: “The iovera° technology enables physicians to treat using only the power of cold which is an appealing option for many.”

“We developed iovera° in partnership with some of the world’s leading physicians. There is powerful consumer demand for the treatment because it offers an immediate wrinkle solution without the use of a toxin,” says Clint.

 

 

ENDS

 

Notes to editors:

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Londoners looking for natural beauty
March 27, 2014 - Read Press Release

Myoscience to Present at the Canaccord Genuity Musculoskeletal Conference

REDWOOD CITY, CA (February 25, 2014)  – California based myoscience, inc., developers of the ioveraº® system for the treatment of peripheral nerve conditions, announced today that Clint Carnell, Chairman and Chief Executive Officer, has been invited to make a presentation at the Canaccord Genuity Musculoskeletal Conference, which will be held on Tuesday, March 11, 2014 at 10:00 am CST at the Sheraton New Orleans.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

 

Myoscience to Present at the Canaccord Genuity Musculoskeletal Conference
February 25, 2014 - Read Press Release

Myoscience to Present at the Cowen and Company 34th Annual Health Care Conference

REDWOOD CITY, CA (February 21, 2014)  – California based myoscience, inc., developers of the ioveraº® system for the treatment of peripheral nerve conditions, announced today that Clint Carnell, Chairman and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA.   Carnell will present on Wednesday, March 5, 2014 at 10:30 am ET.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

 

Myoscience to Present at the Cowen and Company 34th Annual Health Care Conference
February 21, 2014 - Read Press Release

iovera° wins Good Design Award

iovera° wins Good Design Award

 

REDWOOD CITY, CA (January 7, 2014) – Myoscience is pleased to announce that the iovera°® system has won in the medical category of the GOOD DESIGNTM competition. GOOD DESIGN recognizes the world’s most important consumer design products and is one of the most prestigious and oldest design awards. The awards are organized annually by The Chicago Athenaeum Museum of Architecture and Design in cooperation with the European Centre for Architecture, Art, Design and Urban Studies.

Over 700 new products and graphic designs were selected from more than 38 countries for categories including electronics, robotics, children’s products and transportation. The winning entries were awarded for innovation in a variety of areas such as sustainability, creativity, human impact, technology and universal design.

The iovera° system, developed by myoscience, inc. harnesses the power of cold using Focused Cold TherapyTM, the advanced technology that powers the device. The iovera° treatment works immediately for both health and beauty applications without leaving any toxins or chemicals behind in the body. The iovera° system is approved in the European Union and Canada for the treatment of wrinkles, and is FDA cleared for the treatment of pain in the United States.

“The iovera° system was designed to change the way that physicians address the temporary treatment for pain and wrinkles,” says myoscience CEO Clint Carnell. “The Focused Cold Therapytechnology enables physicians to treat using only the power of cold delivered with a simple and intuitive one-button device. The engineers and designers at LUNAR worked hard in collaboration with the myoscience team to ensure we created a beautiful and effective product.” This is the second design award for the iovera° system, following on the heels of the Spark! Design award, where the iovera° system received the highest honors in the general consumer design category.

To see the full list of awards:

http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_MASTER-list.pdf

To see the press release from GOOD DESIGN:

http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_PRESS_INFO.pdf

ABOUT THE GOOD DESIGNTM AWARD

GOOD DESIGN ™ is the world’s most prestigious, recognized, and oldest Design Awards program organized annually by The Chicago Athenaeum Museum of Architecture and Design in cooperation with the European Centre for Architecture, Art, Design and Urban Studies. GOOD DESIGN covers new consumer products designed and manufactured in Europe, Asia, Africa, and North and South America. http://www.chi-athenaeum.org/gdesign/index.html

 

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the iovera° treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The iovera° system has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

 

iovera° wins Good Design Award
January 7, 2014 - Read Press Release

2013

2013

myoscience to Present at the Piper Jaffray 25th Annual Health Care Conference

REDWOOD CITY, CA (November 21, 2013) – California based myoscience, inc., developers of the ioveraº® system powered by Focused Cold TherapyTM for the treatment of peripheral nerve conditions, announced today that it will be participating in the Piper Jaffray 25th Annual Health Care Conference in New York.  Clint Carnell, Chairman and Chief Executive Officer, will discuss myoscience's platform technology using the well-established science of cryoneuromodulation to precisely deliver cold for use in pain management and other peripheral nerve conditions. Mr. Carnell is scheduled to present on December 4, 2013 at 1:30 am ET.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

myoscience to Present at the Piper Jaffray 25th Annual Health Care Conference
November 21, 2013 - Read Press Release

iovera° wins Spark Design Award

 

REDWOOD CITY, CA (November 20th, 2013) – Myoscience is pleased to announce that the design for the iovera° system has won top honors in the Spark International design competition. The iovera° system was awarded the highest honor (Spark!) in the category of product design, which is a general category that includes medical devices as well as consumer electronics, cookware, and even sports equipment.  Myoscience collaborated with LUNAR to design the iovera° system. “We’re honored to have worked with myoscience to design a beautiful and effective device that will help improve the quality of life for countless people,” says Jeff Salazar at LUNAR.

The Spark Awards are given based on two primary criteria: the design innovation and creativity, and the impact it will have on quality of life. The iovera° system is a new take on the safe and reliable use of cold in medicine; by miniaturizing and refining the delivery system to be smaller and more precise, the treatments can be tailored to specific indications. The iovera° system has already improved the quality of life for many who have been treated, immediately reducing pain and enabling people to return to their favorite activities as well as smoothing forehead wrinkles for improved appearance.

The iovera° system, developed by myoscience, inc. in California, harnesses the power of cold using Focused Cold TherapyTM, the advanced technology that powers the device. The iovera° treatment works immediately for both health and beauty applications without leaving any toxins or chemicals behind in the body. iovera° is approved in the European Union and Canada for the treatment of wrinkles, and is used for the treatment of pain in the United States.

“We designed the iovera° system to be sophisticated and intuitive,” says myoscience CEO Clint Carnell. “It has only one button and fits ergonomically in the physician’s hand. Our talented team of engineers and the team of designers at LUNAR who worked hard to ensure we created a product that is not only beautiful to look at, but delivers an elegant result that will immediately ease pain or reduce wrinkles. I am very proud of my team at myoscience who made this concept into a reality.”

To see the full list of awards: http://www.sparkawards.com/about/news/

To see the press release from Spark: http://www.prweb.com/releases/2013/11/prweb11336709.htm

ABOUT THE SPARK AWARD

The Spark mission is to promote better living through better design. The criteria are the same for all Spark competitions: does the design “Spark,” i.e., innovate, change the game and in some way help humanity or the environment we live in. The Spark founders believe Design is an important, relevant tool to help build a better world. We feel that Design and designers act as catalysts, addressing problems and improving our lives and our Earth. www.sparkawards.com

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the iovera° treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. iovera° has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

MKT-0106A

iovera° wins Spark Design Award
November 20, 2013 - Read Press Release

myoscience to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum

REDWOOD CITY, CA (November 11, 2013)  – California based myoscience, inc., developers of the ioveraº® product powered by Focused Cold TherapyTM for the treatment of peripheral nerve conditions, announced today that it will be participating in the Canaccord Genuity Medical Technology & Diagnostics Forum in New York.  Clint Carnell, Chairman and Chief Executive Officer, will present on November 14, 2013 at 1:30 pm ET.

 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system.  The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com

© 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.

myoscience to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
November 11, 2013 - Read Press Release

iovera° treatment for dynamic wrinkles now offered by Drs. Jean & Alastair Carruthers and Doctor Shannon Humphrey

iovera° treatment for dynamic wrinkles now offered by Drs. Jean & Alastair Carruthers and Doctor Shannon Humphrey

REDWOOD CITY, CA (September 17, 2013) – myoscience is pleased to announce that the iovera° treatment is now available from the Vancouver Cosmetic Medicine and Dermatology Clinic, Doctors Alastair and Jean Carruthers and Doctor Shannon Humphrey.

“We are so pleased to work with leading physicians who have numerous published papers on the seminal work done with neurotoxins,” says Clint Carnell, CEO of myoscience. “The Carruthers were instrumental in the development of neurotoxins for cosmetic use and now they have chosen to help bring iovera° to market in Canada and the rest of the world.”

The iovera° treatment is a toxin-free alternative for patients that want to improve their appearance and desire immediate results with nothing left behind in their body. iovera° utilizes Focused Cold TherapyTM , a true platform technology, to stimulate the body’s natural response to cold, temporarily relaxing the muscles that cause wrinkles and block pain signals. The treatment for dynamic wrinkles has been available in the European Union since March of 2013.

Doctor Jean Carruthers feels iovera° will be an important new tool for doctors that want to offer patients options, “We are all familiar with the safety and efficacy of cosmetic neuromodulation using neurotoxins. The iovera° technology is a totally new approach to reducing wrinkles by treating nerves with cold. After some months, the nerves recover and retreatment may be desired." Doctor Shannon Humphrey is enthusiastic to be one of the first to offer the iovera° treatment, “iovera provides us with a new alternative to treat forehead wrinkles in a natural way that provides immediate results, something we feel many patients will find appealing.”

About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

About Vancouver Cosmetic Medicine Doctors Alastair and Jean Carruthers and Doctor Shannon Humphrey are prominent Vancouver physicians specializing in cosmetic medicine; specifically minimally invasive treatments to help our patients look and feel their best. Our practice includes the use of popular cosmetic treatments including Botox Cosmetic®, Xeomin Cosmetic®, Dysport Cosmetic®, tissue fillers, laser and energy-based treatments, and optimized skincare. Dr. Jean and Alastair Carruthers and Dr. Shannon Humphrey are committed to advancing the science of cosmetic medicine. They operate a busy clinical research unit, publish their research regularly in medical journals and lecture to the medical community in Canada and worldwide. The combination of research advancement, clinical teaching and leadership and clinical expertise has helped hundreds of men & women attain successful results. www.carruthers-humphrey.com

iovera° treatment for dynamic wrinkles now offered by Drs. Jean & Alastair Carruthers and Doctor Shannon Humphrey
September 17, 2013 - Read Press Release

Peter Osborne joins myoscience as Chief Financial Officer

Peter Osborne joins myoscience as Chief Financial Officer

Redwood City, CA – September 16, 2013. myoscience, inc. is pleased to announce the addition of Peter Osborne to the team as chief financial officer (CFO). Osborne has over 25 years of experience in high growth public and private companies, most notably with Hansen Medical and VNUS Medical Technologies, and most recently with SentreHEART, Inc.

“Peter has extensive experience in scaling the business, executing global strategy and implementing financial controls to position myoscience for continued success,” said Clint Carnell, CEO of myoscience. “His leadership will help myoscience expand globally and with additional clinical indications.”

Osborne led VNUS through dramatic revenue growth expanding to more than 350 employees and selling into more than 40 countries, culminating in its acquisition by Covidien in 2009. “It is exciting to be joining myoscience at this inflection point in their growth. The positive clinical benefits of Focused Cold TherapyTM experienced by patients and physicians is accelerating market adoption,” said Osborne. “The current strategic needs of the company and my experience in fully realizing the value of innovative technologies fit perfectly to guiding the business to its next stage of commercial success.”

About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Peter Osborne joins myoscience as Chief Financial Officer
September 16, 2013 - Read Press Release

myoscience Announces $25 million Series E Financing Round

Redwood City, CA – September 12, 2013. myoscience, inc., the makers of iovera°, is pleased to announce that it has closed on $25 million in Series E financing. The funds for the Series E financing came entirely from existing investors. The iovera° system uses Focused Cold TherapyTM to treat peripheral nerve conditions for both cosmetic and pain indications.

“We are all excited about the results of iovera° for cosmetic use in the European Union and Canada, and the growing potential of our product in the treatment of focal pain in the United States,” says Clint Carnell, CEO of myoscience. “This financing demonstrates the high degree of commitment and confidence that the investors have in the company’s potential. “

“We are ready and willing to support the future growth of myoscience, expanding geography and indications to recognize the full potential of their platform technology,” says Jan Pensaert of Valiance Asset Management Limited.

The Series E financing included the following existing investors: Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Saratoga Ventures, and Valiance Asset Management Limited.

About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

myoscience Announces $25 million Series E Financing Round
September 12, 2013 - Read Press Release

iovera° treatment for dynamic wrinkles now approved in Canada

REDWOOD CITY, CA (July 18,2013) - iovera°, the world's first toxin-free treatment for dynamic wrinkles utilizing the body's natural response to cold, has received regulatory approval in Canada. Developed by myoscience, inc. in California, the iovera° system targets dynamic forehead wrinkles precisely using Focused Cold Therapy™, an advanced technology that works immediately to temporarily reduce the appearance of wrinkles without leaving any toxins or chemicals behind in the body. The treatment is currently available in the European Union and will be available in Canada soon.

People who want to treat their forehead wrinkles but are uncomfortable with previously available treatments now have a new option with the iovera° system. The treatment only takes about 20 minutes, and is an exciting new solution for those who want a quick toxin-free treatment for dynamic wrinkles

Clint Carnell, CEO of myoscience, can see the excitement that iovera° is already generating with its launch in the EU. “We developed iovera° in partnership with some of the world's leading physicians. There is powerful consumer demand for iovera° because it offers a wrinkle solution that has no toxins and no wait for results, so there's no worry for patients about getting back to their regular lifestyle.”

An early partner and physician using iovera° in his clinic in Paris, France, Dr. Patrick Trevidic says: “I know from experience that there are patients who have hesitations about using botulinum toxin. They still want to treat their wrinkles : iovera° for these patients is a more comfortable option because it injects nothing into the body. It enables me to better serve more of my patients and is a welcome addition to my aesthetic treatment toolbox. Best of all the results are seen immediately which is very exciting.”

About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy™, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

iovera° treatment for dynamic wrinkles now approved in Canada
July 18, 2013 - Read Press Release

iovera° introduced in Europe as the World’s First Toxin-free Treatment for Dynamic Facial Lines

Monaco, 04 April 2013 myoscience, inc. presents European launch of its ground breaking toxin-free treatment, iovera°, at The Anti-Aging Medical World Congress (AMWC) in Monaco.  iovera° is a new tool for aesthetic physicians for the treatment of dynamic facial lines. iovera° immediately reduces the appearance of forehead lines using only the body’s natural response to cold.

iovera° targets facial lines precisely using Focused Cold TherapyTM, an advanced technology that works immediately and temporarily relaxes facial muscles that cause wrinkles without leaving any toxins or chemicals behind in the body. Many people who want to treat their dynamic facial lines but are uncomfortable with previously available treatments now have a new option with iovera°.

Clint Carnell, CEO of myoscience, is excited to see iovera° come alive in the hands of physicians in Europe. “We developed iovera° in partnership with some of the world’s leading physicians. There is powerful consumer demand for a wrinkle solution that has no toxins and no wait for results, so there’s no worry for patients about getting back to their regular lifestyle.”

Dr. Jonathan Sykes, Director of Facial Plastic Surgery, UC Davis Medical Center, California, who will present about iovera° at AMWC says, “Recent in-clinic market research of nearly 4,000 patients demonstrates that the offer of an effective toxin-free, minimally invasive option for dynamic forehead lines is a very attractive proposition. iovera° not only appeals to consumers new to aesthetic procedures, but also to existing patients.” He adds, “iovera° is an exciting breakthrough in medical aesthetics because it will create new opportunities by opening clinic doors to a previously unseen consumer group seeking an effective, quick, toxin-free treatment option.”

iovera° will be available first to physicians in the UK, Germany, the Netherlands, Belgium and France, with planned expansion into the rest of the EU throughout 2013.

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

iovera° introduced in Europe as the World’s First Toxin-free Treatment for Dynamic Facial Lines
April 4, 2013 - Read Press Release

iovera° Approved in Europe, Gains CE Mark

IMCAS, Paris, February 1, 2013. myoscience, inc. has announced the release of iovera° following CE mark approval on 24 January 2013. IMCAS marks the launch of the iovera° brand to medical aesthetic professionals. Developed and produced by myoscience, iovera° is a revolutionary treatment for dynamic facial lines, which provides an immediately visible reduction in wrinkles without leaving any toxins or chemicals behind in the body. The treatment is based upon myoscience’s platformtechnology, Focused Cold Therapy ™. It works by using the body’s natural response to cold to temporarily relax the facial muscles that cause wrinkles.

Clint Carnell, CEO of myoscience, says, “CE approval and launch of the iovera° brand atIMCAS marks a significant milestone for myoscience in paving the way to commercialize our product in Europe. iovera° is an exciting advance meeting the clear need for a toxin-free treatment while expanding treatment choice.”

Speaking at IMCAS, Daniel Cassuto, MD, professor of plastic surgery at the University of Catania in Milan says: “iovera° is an exciting advance in medical aesthetics treatments and is a welcome addition to the physician’s tool box. I know from experience that there are a significant number of patients for whom toxin treatments are not an option; iovera° meets the needs of patients today.”

Focused Cold Therapy™ delivers precise cold to peripheral nerve tissue. Nerves treated with this technology undergo a predictable period of dormancy, followed by complete restoration of function. iovera°treats forehead linesimmediately with results lasting up to 4 months. The procedure is designed for use in a minor treatments room and takes about 15 minutes. iovera° will be first available in select centres of excellence before becoming more widely available across Europe throughout 2013.

iovera° Approved in Europe, Gains CE Mark
February 13, 2013 - Read Press Release

FDA Clearance for Pain Management in Nerve Tissue

REDWOOD CITY, CA (January 22, 2013) – myoscience is pleased to announce that their next generation device has received FDA clearance for treatment of peripheral nerve tissue using Focused Cold Therapy for the blocking of pain.

Focused Cold Therapy, myoscience’s platform technology, relies upon the well-­? established science of cryoneuromodulation to precisely deliver cold to peripheral nerve tissue. Nerves treated with this technology undergo a predictable period of dormancy, followed by complete restoration of function.

“This clearance is a significant milestone for our company, paving the way to commercialize our product in the United States. Our engineers have done a remarkable job harnessing the power of cold within a sophisticated yet simple to use device,” said Clint Carnell, Chief Executive Officer of myoscience.

The effects of Focused Cold Therapy are immediate, with patients experiencing instant pain relief and the ability to return to normal activities with minimal downtime. The myoscience device delivers a precise treatment to the target tissue—there is no diffusion of effect beyond the selected target.

“The potential of Focused Cold Therapy is to provide treatment options for a wide range of patients seeking safe, effective and immediate pain relief without the systemic risks associated with other therapies,” said Dr. Richard Radnovich.

FDA Clearance for Pain Management in Nerve Tissue
January 22, 2013 - Read Press Release

2012

2012

Canaccord Genuity 2012 Medical Technology Forum

myoscience to Present at 2012 Canaccord Genuity Medical Technology Forum

myoscience, inc., the developer of Focused Cold Therapy for the treatment of the peripheral nerve conditions, announced that President & CEO, Clint Carnell, will be presenting at the Canaccord Genuity Medical Technology and Diagnostics Forum to be held on Tuesday, December 4, 2012 at the Le Parker Meridien in New York, NY.

Clint Carnell will speak at 10:00am Eastern time about the upcoming 2013 European Union launch of the company's first aesthetics product for the treatment of wrinkles. Mr. Carnell will also provide an overview of Focused Cold Therapy and the opportunities in therapeutics such as pain and various movement disorders.

The presentation will be webcast live and may be accessed by visiting the myosience website at www.myosience.com

Canaccord Genuity 2012 Medical Technology Forum
November 27, 2012 - Read Press Release

FDA Clearance for Next-Gen Device by myoscience

REDWOOD CITY, CA (July 10, 2012) –The newest generation of myoscience’s novel device technology has received FDA clearance for the treatment of pain. myoscience’s patented technology precisely delivers cold to targeted nerves. The cold induces a hibernating state resulting in a temporary interruption of nerve signaling to sensory receptors or muscle tissue.The device uses the power of cold to achieve an immediate result with nothing left behind in the patient. The myoscience device received CE approval and a medical device license from Health Canada in 2011. The hand-held device is intended for use in the physician’s office and represents a breakthrough advance in the treatment of pain. The myoscience technology can address multiple indications in a targeted treatment with no systemic side effects or addictive potential. “FDA clearance for our device in the US provides myoscience with a platform technology on which to grow our company by addressing further indications and an expanding geography,” said Clint Carnell, Chief Executive Officer of myoscience.

FDA Clearance for Next-Gen Device by myoscience
July 10, 2012 - Read Press Release

Myoscience Closes $33 Million Series D Financing

Funds to commercialize first indication of platform Focused Cold Therapy for forehead wrinkles

REDWOOD CITY, CA, March 21, 2012 – Venture-backed myoscience, Inc. announced that it closed on $33 million in Series D financing and anticipates a second tranche of up to $12 million dollars due to significant interest in the investment community. Myoscience is committed to making its platform technology, focused cold therapy (FCT), the pre-eminent treatment for conditions involving nerves. The company will use the proceeds of the current financing round to commercialize the first indication in Europe, which is a treatment to reduce ‘dynamic facial lines,’ more commonly referred to as forehead wrinkles. Toxin-free FCT is uniquely positioned to expand the aesthetic market for treatment of dynamic facial lines currently addressed by neurotoxins.

Myoscience’s strategy is to establish FCT as a platform technology for multiple indications, starting with the treatment of dynamic facial lines. The company then plans to expand the technology into therapeutic indications for the focal treatment of pain and muscle disorders. The company believes the addressable aesthetic market is approximately $2 billion while the market for the focal treatment of pain and muscle disorders may be up to $9 billion.

“Our financing was significantly oversubscribed -- a marker, we believe, of our company’s significant progress this year and potential in the near future,” said Clint Carnell, myoscience President & CEO. “We look forward to commercializing our aesthetic indication in Europe, and believe that our natural, nontoxin approach will expand the entire category by pulling toxin-averse patients off the sidelines and into the doctor’s office. With the platform complete we can now work with physicians to develop nonaddictive, non-injectable treatments for various therapeutic applications in pain and muscle disorders, an equally exciting and compelling market for our unique technology.”

The Series D financing included the following existing investors: Accuitive Medical Ventures, American Equities Overseas, DeNovo Ventures, Medicis Capital, Nexus Medical Partners, Saratoga Ventures, and Valiance.

Myoscience received CE Mark clearance and its Canadian market license in December 2011 for temporary treatment of wrinkles and the treatment of pain. The company recently submitted a 510k application for the treatment of pain with the U.S. Food and Drug Administration, and will shortly begin to enroll subjects in a pivotal trial to support FDA clearance for treatment of wrinkles. The technology is presently cleared in the U.S. for treatment of peripheral pain syndromes and use in general tissue ablation.

Myoscience Closes $33 Million Series D Financing
March 21, 2012 - Read Press Release

OLDER

2011

Canadian Approval of Cryotherapy Technology

REDWOOD CITY, CA (December 15th, 2011) – Health Canada has issued myoscience a medical device license for myoscience’s PCP 1.0 system for the temporary treatment of wrinkles and pain. Myoscience’s patented technology precisely delivers cold energy to targeted nerves. The nerves revert to a hibernating state resulting in a temporary interruption of nerve signaling to sensory receptors or muscle tissue. The effects are immediate with nothing left behind in the patient. The hand-held device is intended for use in the physician’s office and represents a breakthrough advance relative to older, larger cryotherapy devices. The myoscience design allows for use in superficial tissues that were previously unrealistic targets for older cryotherapy devices.

Canadian Approval of Cryotherapy Technology
December 15, 2011 - Read Press Release

CE Mark for Novel Cryotherapy Technology

REDWOOD CITY, CA (December 7th, 2011) – myoscience’s novel device technology has been granted CE Mark approval for the temporary treatment of wrinkles and pain. Myoscience’s patented technology precisely delivers cold energy to targeted nerves. The nerves revert to a hibernating state resulting in a temporary interruption of nerve signaling to sensory receptors or muscle tissue. The effects are immediate with nothing left behind in the patient. The hand-held device is intended for use in the physician’s office and represents a breakthrough advance relative to older, larger cryotherapy devices. The myoscience design allows for use in superficial tissues that were previously unrealistic targets for older cryotherapy devices. “Approval of our device in Europe is a pivotal achievement that establishes myoscience as a commercial stage company and lays the foundation for global growth,” said Clint Carnell, Chief Executive Officer of myoscience. “In addition to introducing the device in Europe, we are pursuing approval in other international markets and will soon be enrolling subjects in a pivotal trial to support FDA clearance for the wrinkle indication.”

About myoscience. Myoscience is a privately held medical device company dedicated to developing innovative treatments in whichever fields it chooses to enter. Two generations of the myoscience device have already been cleared for use by the FDA.

CE Mark for Novel Cryotherapy Technology
December 7, 2011 - Read Press Release

CBS 4

New Orleans (WWL) — Dr. Posas discusses helping a patient who had suffered from severe headaches for over 5 years.

WCBS

NEW YORK (WCBS) — Freeze the Pain Away. A report from WCBS's Dr. Max Gomez. An avid runner blows her knee out, "she had the knees of a 90 year old man". Nick with a torn ACL and in spite of three surgeries was in constant pain. Dr. Danesh at Mount Sinai Hospital uses iovera's Focused Cold Therapy to freeze the pain away.

KNBC

LOS ANGELES (NBCLA) — When you have chronic knee pain, everything you do hurts. NBC 4's Dr. Bruce Hensel reports on an alternative to addictive pain medicine and surgery. Watch Dr. Williams dramatically improve the knee pain of Sharon Basham-Dominguez by freezing nerves in both knees. This was the first time she felt normal, after years of pain.

THE DOCTORS

A ground breaking treatment that can virtually eliminate your pain in 60 seconds. You won't believe what doctors are using today to treat knee pain, headaches, and more. Is it right for you? Over 100 million Americans suffer from pain. Jennifer, she was another statistic until she found another way. Dr. Vernon Williams shows us a new procedure that actually freezes pain away.

CBS NEW YORK

NEW YORK (CBSNewYork) — Imagine having knee pain for decades, and then having it all disappear with a quick trip to the doctor's office. As CBS 2's Emily Smith reports, doctors are actually freezing away the pain. Watch Dr. Vinod Dasa treat patient Leslie Griffin who has suffered from knee pain since she was 20 years old.

The iovera° beauty treatment is not available in the United States.
 

LONDON BEAUTY HUB

BEAUTY & LIFESTYLE NEWS — The majority of women in London (54%) claim they would be unlikely to go out and meet friends without doing their hair and makeup yet they are not alone as 43% of men confessed that they would not go out without doing their hair. The findings are from a survey of more than 500 Londoners that reveals unique insights into the way men and women in the capital feel about their beauty and grooming regimes. Read Article

PLASTIC SURGERY PRACTICE

THE FACE: IT'S FAUX TOX TIME — iovera° from Myoscience, Redwood City, Calif, delivers Focused Cold Therapy™ as an attractive option for people who want to treat their dynamic forehead wrinkles without a toxin. Currently, it is approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction, and the treatment of dermatologic conditions. iovera° has also been cleared in the US for pain management and general surgical use. Read Article

WOW NOW

FREEZE IT! — The latest beauty trend that's taking plastic surgery clinics by storm vows to offer a natural and rejuvenated result. In essence, this treatment reduces and softens wrinkles without the use of toxins with instant results in just fifteen minutes! In turn, this allows you to resume to the normal, busy schedule of your everyday life. View Article

MY FACE MY BODY

THE NATURAL BEAUTY TREND IN LONDON — A survey conducted by new cosmetic wrinkle treatment iovera°® has found that there is a growing desire among Londoners for more natural beauty products and treatments.  Two thirds of respondents (65%) said that they have become more aware of the ingredients in cosmetics and beauty products in the last two years.  While quality (59%) and price (48%) are important, natural ingredients (32%) ranked highly on factors influencing purchasing decisions. Read Article

EXPRESS

FAT-FREEZING, SHOCK WAVES AND LIGHTBULB FACIALS: THE BRAND NEW BEAUTY TREATMENTS FOR 2014 — Toxin-free wrinkle buster: One of the most tried and tested ways to keep wrinkles at bay is by using a neurotoxin injectable such as Botox. However while this treatment is safe, for many women the thought of injecting toxins and other chemicals into their body is still a big no-no. A new anti-ageing treatment called iovera° may provide a solution. The new 15-minute procedure uses liquid nitrous oxide to temporarily freeze the nerves that move the muscles in the face, helping to smooth lines and wrinkles. Read Article

PRIME

THE EFFICACY OF FOCUSED COLD THERAPY ON HORIZONTAL DYNAMIC FOREHEAD WRINKLES — Vincent Wong and Fabien Giausseran discuss patient improvement and satisfaction following treatment to forehead wrinkles with a Focused Cold Therapy device. Read Article